Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For Class II medical devices, particularly in vitro diagnostics (IVDs), General Controls are often insufficient to provide a reasonable assurance of safety and effectiveness. To address this, the FDA ...
When preparing a premarket submission for a connected medical device, how should sponsors effectively document their cybersecurity approach to meet FDA's expectations for both Quality System integrati...
With new Waste Electrical and Electronic Equipment (WEEE) and Extended Producer Responsibility (EPR) regulations and deadlines emerging in North America and Europe for 2026, manufacturers of medical d...
With significant updates to the ISO 10993-1 standard anticipated around 2026, medical device manufacturers are re-evaluating their approach to establishing biological safety. How should a sponsor dete...
With significant updates to the international standard for biological evaluation, ISO 10993-1, anticipated around 2026, how should medical device manufacturers adjust their biocompatibility assessment...
As the UK's medical device regulatory framework evolves towards a new compliance deadline in 2026, how should non-UK manufacturers re-evaluate the role and responsibilities of their UK Responsible Per...
As non-UK medical device manufacturers navigate the evolving UK regulatory landscape, how can they develop a robust framework for selecting the most suitable UK Responsible Person (UKRP) to ensure com...
What are the key strategic considerations for a non-EU medical device manufacturer when selecting an EU Authorised Representative (AR) under the Medical Device Regulation (MDR)? The MDR mandates that ...
For non-EU medical device manufacturers aiming to place products on the European market, selecting the right EU Authorised Representative (AR) is a critical compliance step under the Medical Device Re...
As global Waste Electrical and Electronic Equipment (WEEE) and Extended Producer Responsibility (EPR) regulations evolve towards 2026 implementation milestones, how should manufacturers of complex ele...
As the landscape of Extended Producer Responsibility (EPR) regulations for electronics, including medical devices, continues to expand across the United States, manufacturers face the complex task of ...
With significant updates to the ISO 10993-1 standard for biological evaluation of medical devices expected, how can device manufacturers effectively audit and select a contract research organization (...
With significant updates to key biocompatibility standards like ISO 10993-1 anticipated to be implemented around 2026, how should medical device manufacturers strategically adjust their biological eva...
For medical device manufacturers based outside the United Kingdom, appointing a UK Responsible Person (UKRP) is a mandatory requirement for placing devices on the Great Britain market. As the UK's reg...
For manufacturers based outside the United Kingdom, appointing a UK Responsible Person (UKRP) is a mandatory step for placing medical devices on the market in Great Britain. While budgeting for this s...
As significant regulatory updates for cosmetic products are anticipated in the European Union, how should a non-EU brand strategically evaluate its EU Responsible Person's (RP) readiness to manage the...
For non-EU medical device manufacturers, what are the key strategic and regulatory responsibilities to evaluate when selecting an EU Authorised Representative (AR) under the Medical Device Regulation ...
When planning for 2025 budgets, many companies processing data from EU residents must account for compliance with European data privacy regulations. A key consideration is the cost of appointing a req...
As non-EU medical device and SaMD companies plan their data protection strategies for 2026, how can they develop a robust evaluation framework for selecting a GDPR Article 27 representative that ensur...
As medical device manufacturers prepare for the upcoming revision of the ISO 10993-1 standard, what are the critical adjustments needed for a compliant biological evaluation strategy? Beyond simply up...